---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-24-000058"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:11:55.422876+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medtronic reports Q4 FY24 revenue $8.59B, organic growth 5.4%; FY25 EPS guidance $5.40-$5.50

## Summary
- Q4 GAAP diluted EPS $0.49, non-GAAP $1.46; FY24 GAAP diluted EPS $2.76, non-GAAP $5.20.
- FY24 revenue $32.4B (+3.6% reported, +5.2% organic); Q4 revenue $8.59B (+0.5% reported, +5.4% organic).
- FY25 guidance: organic revenue growth 4%-5%; non-GAAP EPS $5.40-$5.50 (4-6% growth).
- Dividend increased to $0.70 quarterly ($2.80 annual), 47th consecutive year of dividend increase.
- Broad-based organic growth: Neuroscience +6.5%, Cardiovascular +4.0%, Medical Surgical +4.5%, Diabetes +11.1% in Q4.

## SEC filing metadata
- accession: 0001613103-24-000058
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310324000058/0001613103-24-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310324000058/mdt-20240523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-24-000058
- JSON: https://secwatch.observer/filing/0001613103-24-000058.json
- Plain text: https://secwatch.observer/filing/0001613103-24-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.